Skip to content

LIDDS: Clarification regarding signed research agreement

With reference to press release LIDDS signs research agreementwith major European pharma company, published 21 July 2017 at 10:00 CET, we hereby announce that the agreement party is Ferring Pharmaceuticals.

Contact information
Monica Wallter, CEO,, +46(0)73 7070 922

LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation and the Securities Market Act. The information was submitted through Monica Wallter, for publication on 24 July 2017 at 8:55 CET

LIDDS AB (publ) develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid® releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment. NanoZolid® technology allows for a controlled, sustained and customized release of medication for up to six months. NanoZolid® can integrate both small and large pharmaceutical molecules such as antibodies. The company's most advanced project, the prostate cancer product, Liproca® Depot containing 2-hydroxyflutamide, validates that the technology has a proven clinical effect. The prostate cancer project is currently in phase IIb. Industrial-scale production is produced in collaboration with Recipharm. LIDDS has active development projects where NanoZolid® is combined with antiandrogens, cytotoxic drugs and immuno-active agents. The LIDDS share is listed on Nasdaq, First North. Redeye AB is LIDDS certified adviser.
For more information, please visit

The News in PDF

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LIDDS AB via Globenewswire